Combination treatment of rituximab and donor platelets infusion to reduce donor‐specific anti‐HLA antibodies for stem cells engraftment in haploidentical transplantation

BACKGROUND: Donor‐specific anti‐human leukocyte antigen (HLA) antibodies (DSAs) in recipients is a risk factor for donor stem cell graft failure in haploidentical hematopoietic stem cell transplantation (haplo‐HSCT), and the treatment to reduce the levels of DSAs is not unanimous. This study was to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Rongli, He, Yi, Yang, Donglin, Jiang, Erlie, Ma, Qiaoling, Pang, Aiming, Zhai, Weihua, Wei, Jialin, Feng, Sizhou, Han, Mingzhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370703/
https://www.ncbi.nlm.nih.gov/pubmed/32112480
http://dx.doi.org/10.1002/jcla.23261

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7370703/
https://www.ncbi.nlm.nih.gov/pubmed/32112480
http://dx.doi.org/10.1002/jcla.23261

Ejemplares similares